Newsroom
Dr Fridsma Leaves ONC to Be President and CEO of AMIA
Doug Fridsma, MD, PhD, FACP, FACMI, is leaving his position as the chief science officer for the Office of the National Coordinator for Health Information Technology to become the president and CEO of the American Medical Informatics Association.
Amgen's Blinatumomab Get's Breakthrough Status for ALL
The drug is the first in it's class — an antibody designed to engage 2 different targets simultaneously.
New Graphene Biosensor to Detect Cancer Biomarkers
The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.
Introducing: American Association for Physician Leadership
In response to the growing recognition that physician leadership is essential to the successful transformation of healthcare, the American College of Physician Executives is becoming the American Association for Physician Leadership.
Lower Insurance Rates Saved Consumers $1 Billion in 2013
In 2013, lower health insurance rates saved consumers a total of $1 billion. States that enhanced their rate review programs will receive $25 million in rate review grant awards.
Small-Group Insurance Premium Variations Likely to Continue in the Near-Term
Since 2000, small-group health insurance premiums averaged annual increases of 5.5% nationally; however, double-digit increases were not uncommon, according to a report from the Urban Institute.
Microbubbles: New Carrier for Chemotherapy Delivery
The study, conducted in pancreatic cancer patients in Norway, was presented at the annual meeting of the International Contrast Ultrasound Society in Chicago.
Consumers Find ACA Insurance Plans Affordable
Although a majority of adults with health insurance purchased through the Affordable Care Act’s marketplace said they find it easy to afford the care they need, the number of people still enrolled has dipped to 7.3 million, according to recent numbers.
Gilead's Zydelig Receives EU Nod for CLL and FL
The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.
GAO Report: Healthcare.gov Needs to Address Security Weaknesses
After examining the security and privacy of the Healthcare.gov website and its supporting systems at CMS, the Government Accountability Office published a report with 6 security management and 22 technical security recommendations.
In The Literature: Ramucirumab Improves OS in Advanced Gastric Cancer Patients
The study, published in Lancet Oncology, found that ramucirumab significantly improved survival by over 2 months.
Health IT Interoperability Roadmap in the Works
As part of National Health IT Week, the Office of the National Coordinator for Health IT, outlined its 10-year vision to achieve interoperability for health IT.
In The Literature: SNP Analysis Identifies New Prostate Cancer Susceptibility Loci
The study, published this week in Nature Genetics, is the product of an international collaboration that has identified 23 new loci that could lead to an increased risk of developing prostate cancer.
UK's NICE Wins Drug Price War With GSK
Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
Novo's Long-Acting Insulin, Tresiba, Safe and Effective
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
13% of Hospital Costs Motivated by Malpractice Fear
In a study of 3 hospitals in Massachusetts, more than a quarter of patient orders were considered partially defensive medicine, but they only accounted for 13% of costs.
Study Questions Screening Policy on Mammographically-Dense Breasts in Women
The study, published in the Journal of Clinical Oncology, wants a policy revamp on screening guidelines for the women who fall in this category.
In AJMC, Oster & Fendrick Challenge Designation of High-Value Generic Drugs as “Non-Preferred” Based on Cost, Not Evidence
Putting various branded drugs in “non-preferred” tiers and charging higher copays for them has been used for a number of years to steer consumers to use less costly medicines by giving them “skin in the game.” But authors writing for The American Journal of Managed Care are alarmed by the policies of some insurers that now have designated entire classes of widely used generic drugs “non-preferred,” leaving many patients without any low-cost treatment options for their diseases.
Anthem Blue Cross Launches New Health System with California Hospitals
Anthem Blue Cross is partnering with 7 rival hospital systems in California to create a new integrated health system in the Los Angeles and Orange counties. The members will share financial risk and gain.
Gilead's Simtuzumab Fails in Phase 2
The antibody, an inhibitor of the enzyme lysyl oxidase-like-2, combined with gemcitabine, did not have a significant effect on progression-free survival compared to the placebo with gemcitabine arm, in pancreatic cancer patients.
AMA Seeks EHR Upgrade
The American Medical Association has released a framework to improve usability of electronic health records so as to benefit the patients and providers.
Pioneer ACOs Improve Quality, Earn $68 Million in Shared Savings
During the second year of the program, Medicare accountable care organizations reported improvements in nearly all of the quality and patient experience measures, according to data reported by CMS.
Gilead To License Sovaldi for Cheap in Developing Nations
Gilead has licensed sofosbuvir to drugmakers in India who will sell cheaper versions of this revolutionary treatment in 91 developing nations.
Ascension and Envision Join to Deliver Post-Acute Care
Ascension Health will form a joint venture with a division of Envision Healthcare to provide an array of post-acute services, including home care, hospice care, and infusion therapy.
Alpelisib Provides Promise in Treating Cetuximab-Resistant Head and Neck Cancers
The results of a phase 1b study, presented at the AACR special conference "Targeting the PI3K-mTOR Network in Cancer," found that Alpelisib could overcome resistance to the anti-EGFR antibody cetuximab, and the two regimens together were quite beneficial.